8-K: Xilio Unveils Promising Cancer Therapy Data at SITC

Xilio Therapeutics announced new clinical and preclinical data across its immuno-oncology pipeline, highlighting positive Phase 2 results for vilastobart in colorectal cancer and progress in its T cell engager platform.

Summary

• Vilastobart, in combination with atezolizumab, achieved a 40% objective response rate (ORR) in heavily pre-treated microsatellite stable metastatic colorectal cancer (MSS mCRC) patients without liver metastases and with high plasma tumor mutational burden (TMB).
• A statistically significant correlation (p=0.05) was observed between plasma TMB status and response for vilastobart.
• Approximately 55% of MSS CRC patients are estimated to have high plasma TMB, a significantly higher prevalence than previously estimated by tissue-based assays.
• Vilastobart combination therapy demonstrated a generally well-tolerated safety profile, with primarily Grade 1 or 2 treatment-related adverse events (AEs).
• Preclinical data for Xilio's masked T cell engager platform showed efficient masking, potent anti-tumor activity, and a broad therapeutic index, with programs targeting PSMA, CLDN18.2, and STEAP1.
• Efarindodekin alfa (IL-12) Phase 1 monotherapy data in advanced solid tumors showed encouraging anti-tumor activity, including two partial responses, and was generally well-tolerated at doses over 100-fold greater than the maximum tolerated dose of recombinant human IL-12.
• Circulating tumor DNA (ctDNA) was identified as a potential early predictor for response to vilastobart in combination with atezolizumab, with deep ctDNA reductions (75%) often preceding radiographic responses.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for vilastobart in a challenging cancer type, promising preclinical data for a new platform, and encouraging Phase 1 results for another key asset. The identification of predictive biomarkers and the potential for a broader patient population are significant. The Gilead partnership provides non-dilutive funding potential. The only minor negative is the active search for a vilastobart partner, which could imply resource allocation decisions, but overall, the news is highly positive for a clinical-stage biotech.

Positives

• 40% objective response rate (ORR) for vilastobart in a difficult-to-treat MSS mCRC patient population (without liver metastases and high plasma TMB).
• Statistically significant correlation (p=0.05) between plasma TMB and response, indicating a valuable predictive biomarker.
• Plasma TMB identifies a larger patient population (estimated 55% of MSS CRC) than traditional tissue-based assays.
• Vilastobart combination therapy exhibited a differentiated and generally well-tolerated safety profile, with low rates of discontinuation (5%) and colitis (7%).
• Preclinical data for masked T cell engagers support best-in-class potential with efficient masking, potent anti-tumor activity, and broad therapeutic index.
• Efarindodekin alfa Phase 1 monotherapy showed encouraging anti-tumor activity, including two partial responses, and was well-tolerated at high doses.
• Efarindodekin alfa induced sustained, dose-dependent interferon gamma signaling and transformed the tumor microenvironment.
• ctDNA demonstrated potential as an early and accurate predictor of response to vilastobart, with deep reductions (75%) often preceding radiographic responses.
• Progress in the masked T cell engager pipeline with development candidate nominations for PSMA (Q3 2025) and CLDN18.2 (Q4 2025).
• Gilead license agreement for efarindodekin alfa provides potential for significant milestone payments (up to $500.0 million) and tiered royalties.

Negatives

• Patients in the vilastobart trial were "heavily pre-treated," indicating a challenging patient population where responses are typically harder to achieve.
• The company is actively seeking a partner to develop vilastobart, which could imply resource constraints or a strategic shift away from sole development.

Risks

• General market conditions and geopolitical uncertainties.
• Risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting, or completing preclinical studies and clinical trials, and the timing and results thereof.
• Potential delays of any current or planned preclinical studies or clinical trials or the development of current or future product candidates.
• Ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates.
• Ability to advance multiple early-stage masked T cell engager programs.
• Initial, preliminary, interim, or retrospective preclinical or clinical data or results may not be replicated in or predictive of future preclinical or clinical data or results.
• Ability to successfully demonstrate the safety and efficacy of product candidates and gain approval on a timely basis, if at all.
• Results from preclinical studies or clinical trials for product candidates may not support further development.
• Actions of regulatory agencies may affect the initiation, timing, and progress of current or future clinical trials.
• Ability to obtain, maintain, and enforce patent and other intellectual property protection for current or future product candidates.
• Need to obtain additional cash resources to advance the pipeline of tumor-activated I-O molecules.
• Impact of international trade policies on the business, including U.S. and China trade policies.
• Ability to maintain collaboration or partnership agreements with AbbVie, Gilead, and Roche.

Future Outlook

Xilio Therapeutics plans to actively seek a partner for the development of vilastobart in combination with PD-(L)1 or PD1-VEGF in MSS CRC and other tumor types. The company anticipates nominating development candidates for its CLDN18.2 program in Q4 2025 and for its STEAP1 program in H1 2026, with Investigational New Drug (IND) applications for at least two masked T cell engager programs expected in 2027. Enrollment for Phase 1A/1B monotherapy dose escalation and expansion for efarindodekin alfa is complete, and Phase 2 monotherapy dosing has commenced.

Management Comments

• "These compelling new Phase 2 data for vilastobart in combination with atezolizumab demonstrated a 40% objective response rate in heavily pre-pretreated patients with MSS mCRC without liver metastases and with high plasma TMB, signifying an important advance in our understanding of response to novel immunotherapy in MSS mCRC." Katarina Luptakova, M.D., chief medical officer of Xilio.
• "We estimate that approximately 55% of patients with MSS CRC have high plasma TMB, representing a meaningful patient population who could ultimately benefit from combination treatment with vilastobart and a substantially greater prevalence of patients with high TMB than previously estimated using traditional tissue-based assays." Katarina Luptakova, M.D., chief medical officer of Xilio.
• "These new data highlight the potential to use plasma TMB as a predictive biomarker and identify patients with MSS mCRC who may benefit from treatment with vilastobart, a tumor-activated anti-CTLA-4, in combination with a PD-(L)1." Diwakar Davar, M.D., Associate Professor of Medicine, Clinical Director of the Melanoma Program and Medical Oncologist/Hematologist at the UPMC Hillman Cancer Center.
• "We are incredibly proud to present data at SITC showcasing the depth of our differentiated pipeline of innovative masked immunotherapies and the broad potential for our proprietary masking technology across a wide range of therapies and modalities." Ren Russo, Pharm.D., president and chief executive officer of Xilio.
• "New preclinical data across multiple targets for our masked T cell engager programs further validate the best-in-class potential of our masking technology to not only meaningfully widen the therapeutic window for T cell engagers, but also add co-stimulation to substantially improve durability of T cell response." Ren Russo, Pharm.D., president and chief executive officer of Xilio.
• "In addition, data presented for our clinical-stage programs, efarindodekin alfa, our tumor-activated IL-12, and vilastobart, our tumor-activated, Fc-enhanced anti-CTLA-4, highlight the promising clinical profiles for each of these molecules, as well as our continued excellence in clinical execution." Ren Russo, Pharm.D., president and chief executive officer of Xilio.

Industry Context

The announcements position Xilio Therapeutics at the forefront of developing next-generation immuno-oncology therapies, particularly in addressing challenging cancer types like MSS mCRC, which historically responds poorly to traditional immune checkpoint inhibitors. The focus on tumor-activated (masked) therapies aims to overcome systemic toxicity issues common with current I-O treatments, potentially expanding the therapeutic window. The use of plasma TMB and ctDNA as predictive biomarkers aligns with broader industry trends towards personalized medicine and non-invasive monitoring in oncology. The development of masked T cell engagers and tumor-activated IL-12 therapies represents innovative approaches to enhance anti-tumor immunity.

Comparison to Industry Standards

• The 40% ORR for vilastobart in heavily pre-treated MSS mCRC patients without liver metastases and with high plasma TMB is a significant improvement compared to historical outcomes in this difficult-to-treat population, where tissue-based TMB assays have not shown predictive utility and response rates to immune checkpoint inhibitors are typically low.
• The estimated 55% prevalence of high plasma TMB in non-MSI-H CRC patients, based on GuardantINFORM data, is substantially greater than the <10% TMB-high prevalence suggested by historical tissue-based TMB assays in MSS mCRC, indicating a broader patient population for this biomarker-guided approach.
• Efarindodekin alfa has been administered at doses more than 100-fold greater than the maximum tolerated dose of recombinant human IL-12, demonstrating a significantly improved therapeutic index due to its tumor-activated design.
• Xilio's masked T cell engager programs aim to significantly expand the therapeutic window for T cell engagers and overcome challenges associated with current, systemically active non-masked T cell engagers, which often have dose-limiting toxicities.

Stakeholder Impact

• Shareholders: Positive clinical data and pipeline progress could lead to increased investor confidence and potential share price appreciation. The Gilead license agreement offers future non-dilutive revenue streams.
• Patients: The promising results for vilastobart in MSS mCRC and efarindodekin alfa in advanced solid tumors offer potential new treatment options for difficult-to-treat cancers, potentially improving outcomes.
• Medical Community: The identification of plasma TMB and ctDNA as predictive biomarkers could refine treatment strategies and patient selection in immuno-oncology.
• Partners (Roche, Gilead, AbbVie): Continued positive data strengthens existing collaborations and validates the potential of Xilio's platform.

Next Steps

• Xilio will host a conference call and webcast on November 10, 2025, to discuss the new Phase 2 combination data for vilastobart and other portfolio updates.
• Actively seeking a partner to develop vilastobart in combination with PD-(L)1 or PD1-VEGF in MSS CRC and other tumor types.
• Anticipate nominating development candidates for the CLDN18.2 program (ATACR format) in Q4 2025.
• Anticipate nominating development candidates for the STEAP1 program (SEECR format) in H1 2026.
• Anticipate advancing at least two masked T cell engager programs into IND-enabling studies and submitting IND applications for those programs in 2027.
• Evaluation of patients in Phase 1A monotherapy dose escalation and Phase 1B monotherapy dose expansion for efarindodekin alfa is ongoing.
• Phase 2 portion of the efarindodekin alfa clinical trial, evaluating it as a monotherapy in patients with certain advanced solid tumors, has initiated dosing.

Key Dates

Recommendation

The company has reported highly encouraging clinical data for vilastobart in a challenging indication (MSS mCRC), demonstrating a significant objective response rate and identifying a robust predictive biomarker (plasma TMB) that expands the addressable patient population. This is a substantial de-risking event for the program. Additionally, the preclinical data for the masked T cell engager platform show "best-in-class potential," and efarindodekin alfa's Phase 1 results are promising, supported by a valuable partnership with Gilead. The overall pipeline progress, combined with a differentiated technology platform designed to improve therapeutic index, suggests strong future growth potential. For a seasoned investor, these results indicate a compelling investment opportunity in a clinical-stage biotechnology company with multiple promising assets.

Keywords

Immuno-oncology, cancer therapy, clinical trial, Phase 2, vilastobart, atezolizumab, MSS mCRC, colorectal cancer, plasma TMB, tumor mutational burden, biomarker, T cell engager, efarindodekin alfa, IL-12, ctDNA, circulating tumor DNA, biotechnology, Xilio Therapeutics, SITC, oncology, masked immunotherapy